Second dupixent® (dupilumab) phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease

Tarrytown, n.y. and paris, oct. 25, 2021 /prnewswire/ --  dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first phase 3 trial eosinophilic esophagitis is a progressive disease that damages the esophagus and impairs the ability to swallow; 90% of trial participants had at least one coexisting type 2 inflammatory condition such as asthma or atopic dermatitis dupixent is the only biologic medicine to show positive, clinically meaningful phase 3 results in these patients; regulatory filings planned for 2022 regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced results from a second phase 3 trial assessing the investigational use of dupixent® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (eoe).
REGN Ratings Summary
REGN Quant Ranking